Former Food and Drug Administration (FDA) Commissioner Scott Gottlieb said Johnson & Johnson’s new single-dose coronavirus vaccine “looks like a good profile for a vaccine.”
“Overall, all of this looks like a good profile for a vaccine,” Gottlieb told CNBC’s “Squawk Box” on Thursday after early data showed promising results for the Johnson & Johnson vaccine. “It’s an indication that we’ll probably have a third participant here.”
“All in all, it looks like a good profile for a vaccine,” he says @ScottGottliebMD on early data from the Johnson & Johnson single-dose COVID-19 vaccine. “It’s an indication that we’ll probably have a third participant here.” pic.twitter.com/oFzLQ0PgHV
– Squawk Box (@SquawkCNBC) January 14, 2021
Gottlieb is on board Pfizer, which has produced one of two vaccines that have already received emergency authorization from the FDA.
The results of early-stage studies for the Johnson & Johnson vaccine were published Wednesday in The New England Journal of Medicine. This one he showed that all study participants had neutralizing antibodies in their system after 57 days.
The Johnson & Johnson vaccine would allow the spread of several vaccines and would require only one injection, while the current COVID-19 vaccines from Pfizer and Moderna require two.
The company says more results on their vaccine could come immediately after the end of January. The vaccine has been found to have common side effects, such as headaches and fatigue.
There were plans for the company to have 12 million doses by the end of February, but manufacturing problems could delay this until the end of April.
Vaccines are currently administered at lower rates than anticipated due to strict guidance on who is allowed to receive them. Officials hope that the guidelines will relax in the next few weeks as the number of people receiving the vaccine increases.